Optimising IBD patient selection for de-escalation of anti-TNF therapy to immunomodulator maintenance.

Rachael SwannAlan BoalSeth Ian SquiresCarly LambLaura Louise ClarkSelina LamontGraham Naismith

Published in: Frontline gastroenterology (2019)

The BRP approach has proved a safe and effective means of decision making in stopping biologic therapy. Future work to inform exclusion criteria is required.

Keyphrases

rheumatoid arthritis
case report
clinical trial
stem cells
randomized controlled trial
current status
open label
cell therapy
study protocol
double blind
smoking cessation